CVRx, Inc. (CVRX)

NASDAQ: CVRX · IEX Real-Time Price · USD
21.44
+0.04 (0.19%)
Feb 27, 2024, 11:29 AM EST - Market open
0.19%
Market Cap 447.85M
Revenue (ttm) 39.30M
Net Income (ttm) -41.20M
Shares Out 20.93M
EPS (ttm) -1.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 33,603
Open 21.31
Previous Close 21.40
Day's Range 21.14 - 21.72
52-Week Range 8.38 - 33.14
Beta 1.42
Analysts Strong Buy
Price Target 33.67 (+57.04%)
Earnings Date Jan 25, 2024

About CVRX

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 an... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Jun 30, 2021
Employees 200
Stock Exchange NASDAQ
Ticker Symbol CVRX
Full Company Profile

Financial Performance

In 2023, CVRx, Inc.'s revenue was $39.30 million, an increase of 74.89% compared to the previous year's $22.47 million. Losses were -$41.20 million, -0.55% less than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CVRX stock is "Strong Buy." The 12-month stock price forecast is $33.67, which is an increase of 57.04% from the latest price.

Price Target
$33.67
(57.04% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new Presi...

27 days ago - GlobeNewsWire

CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation soluti...

4 weeks ago - GlobeNewsWire

CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024

MINNEAPOLIS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an inno...

6 weeks ago - GlobeNewsWire

CVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference

MINNEAPOLIS, Dec. 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation soluti...

2 months ago - GlobeNewsWire

CVRx receives FDA approval for expanded labeling of Barostim

U.S. annual market opportunity increases based on real world adoption and strength of long-term BeAT-HF data U.S. annual market opportunity increases based on real world adoption and strength of long-...

2 months ago - GlobeNewsWire

CVRx to Present at the 35th Annual Piper Sandler Healthcare Conference

MINNEAPOLIS, Nov. 15, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...

3 months ago - GlobeNewsWire

CMS Increases Outpatient Payment for Barostim Procedure

MINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services (CMS) has...

4 months ago - GlobeNewsWire

CVRx Reports Third Quarter 2023 Financial and Operating Results

MINNEAPOLIS, Oct. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...

4 months ago - GlobeNewsWire

CVRx to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call on October 26th, 2023

MINNEAPOLIS, Oct. 12, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an inno...

4 months ago - GlobeNewsWire

CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference

MINNEAPOLIS, July 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...

7 months ago - GlobeNewsWire

CVRx Reports Second Quarter 2023 Financial and Operating Results

MINNEAPOLIS, July 25, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...

7 months ago - GlobeNewsWire

CVRx to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call on July 25th, 2023

MINNEAPOLIS, July 11, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an inno...

8 months ago - GlobeNewsWire

CVRx Set to Join Russell 2000 & 3000 Indexes

MINNEAPOLIS, June 22, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...

8 months ago - GlobeNewsWire

CVRx to Present at the William Blair 43rd Annual Growth Stock Conference

MINNEAPOLIS, May 25, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromod...

9 months ago - GlobeNewsWire

CVRx Reports First Quarter 2023 Financial and Operating Results

MINNEAPOLIS, April 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neurom...

10 months ago - GlobeNewsWire

CVRx to Report First Quarter 2023 Financial and Operating Results and Host Conference Call on April 27th, 2023

MINNEAPOLIS, April 20, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an inn...

11 months ago - GlobeNewsWire

Totality of Evidence from BeAT-HF Study Shows CVRx's Barostim Provides Long-term Benefits for Patients with Heart Failure

MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an in...

1 year ago - GlobeNewsWire

CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call

MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extrava...

1 year ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX

NEW YORK , March 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX). Such investors are advised to contact Rob...

1 year ago - PRNewsWire

Bronstein, Gewirtz & Grossman, LLC Notifies CVRx, Inc. (CVRX) Investors of Investigation

NEW YORK--(BUSINESS WIRE)---- $CVRX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors of CVRx, Inc. (“CVRx” or “the Compan...

1 year ago - Business Wire

CVRx stock tumbles after trial for heart failure therapy failed to meet primary endpoing

Shares of CVRx Inc. CVRX, -1.71% tumbled 33.7% in premarket trading Tuesday, putting them on track for a record one-day selloff, after the medical device company said a trial of its BeAT-HF therapy fo...

1 year ago - Market Watch

CVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial

The trial did not meet its primary endpoint, however, the totality of data supports Barostim's use as an effective treatment for patients with heart failure The trial did not meet its primary endpoint...

1 year ago - GlobeNewsWire

CVRx Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

Fourth Quarter 2022 Revenue of $7.2 million, a 96% Increase Over Prior Year Fourth Quarter 2022 Revenue of $7.2 million, a 96% Increase Over Prior Year

1 year ago - GlobeNewsWire

CVRx to Report Fourth Quarter and Fiscal Year 2022 Financial and Operating Results and Host Conference Call on January 26, 2023

MINNEAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation soluti...

1 year ago - GlobeNewsWire

CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results

MINNEAPOLIS, Jan. 09, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation soluti...

1 year ago - GlobeNewsWire